stockrowImmunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
Follow IMVT
Alert me
Immunovant, Inc. (IMVT) Return on equity
Immunovant, Inc.'s return on equity over the twelve months to 30 June 2026 was −80.1%, down 15.3 percentage points from fiscal 2026 (−64.8%). Over the past ten years it has ranged from −776.8% (fiscal 2019) to −0.01% (fiscal 2018); the current reading is higher than 33% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2026 | −64.8% | (2.36) |
| FY2025 | −62.5% | (9.55) |
| FY2024 | −52.9% | (2.22) |
| FY2023 | −50.7% | (14.30) |
| FY2022 | −36.4% | 7.86 |
| FY2021 | −44.3% | 86.68 |
| FY2020 | −130.9% | 645.84 |
| FY2019 | −776.8% | (776.76) |
| FY2018 | −0.01% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 61.1% |
| LGND Ligand Pharmaceuticals Incorporated compare | 5.38% |
| MANE Veradermics Incorporated compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| CGON CG Oncology, Inc. compare | −26.4% |
| IMVT Immunovant, Inc. | −80.1% |
| IONS Ionis Pharmaceuticals, Inc. compare | −105.5% |
| KOD Kodiak Sciences Inc. compare | −368.4% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −760.0% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)